Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Jazz Pharmaceuticals PLC
Cost of Revenue
Jazz Pharmaceuticals PLC
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Cost of Revenue
-$402.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-14%
|
|
Perrigo Company PLC
NYSE:PRGO
|
Cost of Revenue
-$2.9B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Cost of Revenue
-$2.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-22%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Cost of Revenue
-€39.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
Ovoca Bio PLC
LSE:OVB
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Jazz Pharmaceuticals PLC's Cost of Revenue?
Cost of Revenue
-402.4m
USD
Based on the financial report for Mar 31, 2024, Jazz Pharmaceuticals PLC's Cost of Revenue amounts to -402.4m USD.
What is Jazz Pharmaceuticals PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-14%
Over the last year, the Cost of Revenue growth was 27%. The average annual Cost of Revenue growth rates for Jazz Pharmaceuticals PLC have been -36% over the past three years , -27% over the past five years , and -14% over the past ten years .